아라키돈산

6.98

6.98

Liquid; [Merck Index]

Liquid

182.1 Ų [M-H]- [CCS Type: DT; Buffer gas: N2; Sample Type: Human bronchoalveolar lavage fluid (BALF); Dataset: Unambiguous Lipids]

178.94 Ų [M-H]- [CCS Type: DT; Method: single field calibrated with Agilent tune mix (Agilent)]

182.21 Ų [M-H]- [CCS Type: DT; Method: stepped-field]

183.66 Ų [M-H]- [CCS Type: DT; Method: stepped-field]

179.8 Ų [M+Na]+；181.6 Ų [M-H]-；183 Ų [M-H]-

This chemical does not meet GHS hazard criteria for 10.3% (4 of 39) of reports.

Warning

H302 (84.6%): Harmful if swallowed [Warning Acute toxicity, oral]；H312 (82.1%): Harmful in contact with skin [Warning Acute toxicity, dermal]；H315 (89.7%): Causes skin irritation [Warning Skin corrosion/irritation]；H319 (89.7%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]；H332 (79.5%): Harmful if inhaled [Warning Acute toxicity, inhalation]；H335 (84.6%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation]

P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P317, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 39 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.；Reported as not meeting GHS hazard criteria per 4 of 39 reports by companies.；There are 5 notifications provided by 35 of 39 reports by companies with hazard statement code(s).；Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.

Chemical: 5,8,11,14-Eicosatetraenoic acid, (all-Z)-

5,8,11,14-Eicosatetraenoic acid, (5Z,8Z,11Z,14Z)-: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

The safety of this ingredient has not been documented and substantiated for cosmetic product use. The CIR Expert Panel cannot conclude whether Arachidonic Acid is safe for use in cosmetic products until such time that the appropriate safety data have been obtained and evaluated.

Ingredients for which the data are insufficient and their use in cosmetics is not supported

Chemical: 5,8,11,14-Eicosatetraenoic acid, (all-Z)-

5,8,11,14-Eicosatetraenoic acid, (5Z,8Z,11Z,14Z)-: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

Acetaminophen Action Pathway；Acetylsalicylic Acid Action Pathway；alpha-Linolenic acid metabolism；Antipyrine Action Pathway；Antrafenine Action Pathway；Arachidonic Acid Metabolism；Bromfenac Action Pathway；Carprofen Action Pathway；Celecoxib Action Pathway；Diclofenac Action Pathway；Total 43 pathways, visit the HMDB page for details

CIR ingredient: Arachidonic Acid

Essential fatty acid for animals and humans; Used as a nutrient and for the treatment of eczema in dogs and swine; [Merck Index]